Modality
ERT
MOA
MALT1i
Target
USP1
Pathway
Innate Imm
Atopic DermHSDravet
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
~Mar 2020
→ ~Jun 2021
Phase 2
Sep 2021
→ Feb 2031
Phase 2Current
NCT04181919
2,685 pts·Dravet
2021-09→2031-02·Not yet recruiting
NCT03446148
112 pts·Dravet
2024-02→2030-10·Completed
2,797 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-10-184.6y awayPh2 Data· Dravet
2031-02-164.9y awayPh2 Data· Dravet
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2030-10-18 · 4.6y away
Dravet
Ph2 Data
2031-02-16 · 4.9y away
Dravet
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04181919 | Phase 2 | Dravet | Not yet recr... | 2685 | ORR |
| NCT03446148 | Phase 2 | Dravet | Completed | 112 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A |